Performance and Safety of Semical Dermal Fillers in Facial Rejuvenation

Inclusion Criteria: * Aged greater than or equal to 18 years * Female or male * Volunteers in good general health * Volunteers with soft tissue deficits on mid-face that can be corrected with volume restoration * Volunteers who evaluated by investigator as suitable for hyaluronic acid filler applications on her/his lips, nasolabial folds, temporal, perioral, periocular areas * Individuas who have not filler, botulinum toxin, laser, chemical peeling or surgery in the 6 months before the Semical dermal filler application * No permanent or non-permanent asthetic applications (chemical peeling, dermabrasion, ablative laser application) non-invasive face-lift, botulinum toxin injections, mesotherapy or fat injections after or simultaneously with filler application * Volunteers who have not had non-resorbable filler applied before * Volunteers who have complete records regarding the criteria to be evaluated in the study * Volunteers who do not have heavy and misleading make-up in their before and after photos * Volunteers who have not made significant lifestyle changes (diet, physical activity, permanent make-up application) * No exposure to extreme temperatures such as sunlight, UV solarium, laser, extreme cold, sauna, Turkish baths * All Fitzpatrick skin types Exclusion Criteria: * Patients under 18 years of age * Presence of impairment of wound healing or blood flow * Known history of allergy to the study product (hyaluronic acid), local anesthetic used (lidocaine) or gran-positive streptococcal proteins * Presence or history of keloid formation tendency, hypertrophic scar, shromatosis or discoloration * Skin disease with pronounced skin pigmentation * Connective tissue disorders * Coagulation disorders * Existing inflammation / infection at the injection site * Frequently recurring facial / labial herpes * Permanent or semi-permanent tendon, bone and muscle implants near the area to be application * History of allergy in the mouth area * Active autoimmune disease or immunosuppressed individuals with immune system problems * Diabetes mellitus or uncontrolled systemic disease (endocrine, hepatic, renal, cardiac pulmonary or neurological disorders) * Volunteers with acute inflammatory conditions or infections, active herpes infection or history of chronic and recurrent infections * Concomitant medications that affect blood circulation (e.g. aspirin, NSAIDs, Vitamin E, topical and systemic corticosteroids, narcotic antidepressants, immunosuppressive drugs; excluding hormonal and contraceptive treatments started before 1 year) and medications and treatments have the potenrial to affect treatment aoutcomes according to the investigator's opinion * Known alcohol or drug abuse * Subjects who are pregnant or breasfeeding * Subjects who have received COVID-19 vaccination within 30 days before dermal filler application * Epilepsy or porphyria, congenital or idiopathic methemoglebinemia, or glucose-6-phosphate dehydrogenase deficiency * Analgesic dependence or need for continuous use * Syphilis or HIV infection * Subjects who have undergone medication or surgical treatments that may cause significant changes in body weight after dermal filler application (such as bariatric surgery)